BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...
Medpage Today on MSN19h
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free SurvivalAdding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...
Finally, the assay can be used with Merck’s Keytruda (pembrolizumab) and GSK’s Jemperli (dostarlimab) across solid tumors ...
GlobalData on MSN13h
MSD and AstraZeneca report positive topline data from Koselugo trial for NF1Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...
Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on IO Biotech (IOBT – Research Report), retaining the price target of ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Pipeline and key clinical candidates for these companies: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback